News
DifGen Pharmaceuticals Acquires Aveva Drug Delivery Systems, strengthens its Position in offering Difficult and Differentiated Pharmaceuticals Dosage Forms with a US-based Development and Manufacturing Capability.
READ MOREAbout Us
We are a US based Global Pharmaceutical company with a primary focus on developing complex high barrier to entry Generics and Specialty Pharmaceutical products that would help increase accessibility to high quality medication thereby leading to the creation of next generation healthy communities. We are driven by an earnest pursuit of redefining the accepted standards in pharmaceutical product development and commercialization. We consistently aspire to challenge standard thought processes to arrive at dependable solutions that create a paradigm shift in product development, quality, clinical affairs, regulatory sciences, and commercial strategy. Our talented team with some of the brightest minds have developed a holistic understanding of the nuances associated with the development of unique, commercially viable and difficult product lines across varying therapeutic areas and a broad array of dosage forms such as Injectables, Ophthalmics, Topicals, Biologicals, Drug Devices, Soft Gels, Solid Orals & Suspensions. DifGen Pharmaceuticals Acquires Aveva Drug Delivery System Inc. Aveva Drug Delivery Systems is a fully integrated developer and manufacturer of Transdermal Delivery Systems (TDS) and oral Dissolvable Films (ODF). Aveva is licensed to manufacture, package and market OTC & Rx TDS and ODF products in the USA & Canada and is DEA approved for Schedule II & III controlled substance storage & handling. Aveva’s licensed facilities located in Miramar, FL is spread across 3 sites totaling 144,000 sq. ft with current installed capacity of ~100m Patches per annum.
